Tauopathies Treatment Market
Tauopathies are a diverse category of neurodegenerative disorders distinguished by abnormal tau protein metabolism (tau prions) that ultimately leads to a significant loss of brain cells. The "microtubules" of the cell are stabilized by tau proteins. Misfolding causes intracellular buildup and the development of faulty Neurofibrillary Tangles (NFT), which are no longer able to stabilize the microtubules. Tau proteins are more prevalent in the central nervous system's neurons than they are elsewhere. There are currently no disease-modifying therapies for the treatment of tauopathies. Tauopathies are result of aggregation and precipitation of misfolded tau proteins that normally stabilize neural microtubule. These aggregates form neurofibrillary tangles that lead to neuronal toxicity and degeneration. Neurofibrillary tangles are abnormal cytoplasmic accumulation of tau proteins found in neuronal and glial cells of central nervous system. The term primary tauopathy refers to disorders in which tau protein deposition is the predominant feature. Diseases characterized by tau pathologies considered as having another and diverse driving force are also called secondary tauopathies. Diagnosis is based on neuropathological features, mainly Parkinson’s disease and dementia in later stage. There is a significant clinical overlap between different tauopathies.
Market Dynamics
Increasing launches of new products, and mergers and acquisitions by key market players are expected to drive the global tauopathies treatment market growth. For instance, on July 29, 2020, UCB S.A., a Europe-based global biopharmaceutical company, announced an agreement to enter into a worldwide, exclusive license agreement with F. Hoffmann-La Roche Ltd, a Switzerland-based global pharmaceuticals and diagnostics company, and Genentech, Inc., a U.S.-based biotechnology corporation and a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer’s Disease (AD). UCB0107 is an investigational monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. The transaction remains subject to obtaining antitrust clearance and other customary closing conditions. UCB will provide an exclusive, worldwide license to F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize UCB0107 in Alzheimer’s Disease . In return, UCB S.A will receive an initial upfront payment of US $120 million.
Key features of the study:
Detailed Segmentation:
Table of Contents
*Browse 32 market data tables and 31 figures on “Tauopathies Treatment Market” - Global forecast to 2030
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients